Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | DRD1 | P21728 | 2/20 | 0.61 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | DRD5 | P21918 | 1/20 | 0.54 |
| ▸ | PNMT | P11086 | 4/20 | 0.53 |
| ▸ | CD44 | P16070 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.48 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.48 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.48 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.48 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.48 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.48 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.48 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017452 | 0.98 | DRD2 (0.62) | DRD2DRD1ASIC3DRD3DRD4 | |
| SCHEMBL29514775 | 0.98 | DRD2 (0.62) | DRD2DRD1ASIC3DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL31336072 | 0.96 | DRD2 (0.61) | DRD2DRD1ASIC3DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL453336 | 0.96 | DRD2 (0.61) | DRD2DRD1ASIC3DRD3DRD4 | |
| Bromide SCHEMBL6190676 | 0.92 | PNMT (0.63) | DRD2DRD1DRD3DRD4DRD5 | |
| SCHEMBL470826 | 0.90 | PNMT (0.66) | DRD2DRD1DRD3DRD4DRD5 | |
| Oxalic Acid SCHEMBL6952790 | 0.89 | DRD2 (0.54) | DRD2DRD1ASIC3DRD3DRD4 | |
| Bromide SCHEMBL6071099 | 0.89 | DRD2 (0.59) | DRD2DRD1ASIC3DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL2675120 | 0.88 | PNMT (0.63) | DRD2DRD1DRD3DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL30955057 | 0.88 | PNMT (0.63) | DRD2DRD1DRD3DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-11161819-B2 | Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2021-11-02 | — | — | US | disclosed |
| CN-112839714-A | Chromen-4-one derivatives for the treatment and prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20200347020-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-11-05 | — | — | US | disclosed |
| WO-2020079106-A1 | CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-23 | — | — | WO | disclosed |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2020-02-04 | — | — | US | disclosed |
| US-20190161448-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-05-30 | — | — | US | disclosed |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3463362-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3164395-B1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-5403846-A | Antiarrhythmic agents | MERCK & CO., INC. (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0641324-A1 | TETRAHYDRO AND PERHYDRO ISOQUINOLIN DERIVATIVES AND THERAPEUTIC AGENTS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994020459-A2 | PYRROLO-PYRIDINE DERIVATIVES AS DOPAMINE RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
| CN-1085214-A | Tetrahydrochysene one and perhydro isoquinilone derivatives and the therapeutic composition that contains these compounds | BASF AG (DE) | 1994-04-13 | — | — | CN | disclosed |
| WO-1993024461-A1 | TETRAHYDRO AND PERHYDRO ISOQUINOLIN DERIVATIVES AND THERAPEUTIC AGENTS CONTAINING THEM | BASF AKTIENGESELLSCHAFT (DE) | 1993-12-09 | — | — | WO | disclosed |
| EP-0422666-A2 | 6-Substituted-1,2,3,4-tetrahydroisoquinolines | ABBOTT LABORATORIES (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4963563-A | TREATING GLAUCOMA; INHIBITORS OF ALPHA-2-ADRENERGIC RECEPTORS | ABBOTT LABORATORIES (US) | 1990-10-16 | — | — | US | disclosed |
| US-4717724-A | FUNGICIDES, ANTIPROTOZOA, BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-05 | — | — | US | disclosed |
| EP-0121753-A2 | 1-(1,3-Dioxolan-2-ylmethyl)-azoles, their salts, processes for their preparation and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-10-17 | — | — | EP | disclosed |
| US-4013663-A | BETA-RECEPTOR BLOCKING AGENTS | KNOLL A.G. CHEMISCHE FABRIKEN (DT) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161448-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | ADRA2A 107/4885ADRA2B 131/4885ADRA2C 106/4885 |
| US-11161819-B2 | Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists | GPR119, GPR88, GPR180 | ADRA2A 106/4885ADRA2B 123/4885ADRA2C 104/4885 |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | ADRA2A 100/4885ADRA2B 143/4885ADRA2C 81/4885 |
| US-20200347020-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | ADRA2A 106/4885ADRA2B 123/4885ADRA2C 104/4885 |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | ADRA2A 100/4885ADRA2B 143/4885ADRA2C 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.